Accumetrics completes enrollment stage of GRAVITAS clinical trial Accumetrics, Inc.g., coronary attack, stent thrombosis) following percutaneous coronary intervention .S. And Canada, and has enrolled approximately 2,800 individuals. We are thrilled to have concluded the enrollment phase of the GRAVITAS trial, said Jeff Dahlen, Ph.D., Vice President, Regulatory and Clinical Affairs of Accumetrics. Â.While some populations are disproportionately affected, people from all segments of society can get the condition. A relative insufficient financing for disease surveillance and educational efforts is a major barrier towards eradication of hepatitis B and C. Among the recommendations created by the nonpartisan, scientific panel are that major new efforts must include increased funding for education and analysis of the population, policy manufacturers, and the medical community. Furthermore, the IOM recommends that there become new, adequately funded programs for identification and surveillance of these with viral hepatitis.